847608-28-0 Usage
Description
4,5,6-Trichloronicotinic acid is a chemical compound with the formula C6H2Cl3NO2. It is a trichlorinated derivative of nicotinic acid, which is a precursor to the coenzyme nicotinamide adenine dinucleotide (NAD).
Used in Pharmaceutical Industry:
4,5,6-Trichloronicotinic acid is used as an intermediate in the synthesis of pharmaceuticals for its potential role in the development of new drugs.
Used in Agrochemical Industry:
4,5,6-Trichloronicotinic acid is used as an intermediate in the synthesis of agrochemicals, contributing to the creation of products for agricultural applications.
Used as a Herbicide:
4,5,6-Trichloronicotinic acid has been studied for its potential as a herbicide, indicating its possible use in controlling, preventing, or killing unwanted plants.
Used as an Insecticide:
4,5,6-Trichloronicotinic acid has also been studied for its potential as an insecticide, suggesting its possible application in managing and controlling insect populations.
Safety and Handling:
4,5,6-Trichloronicotinic acid is considered to be moderately hazardous, and it is crucial to take proper safety precautions when handling it. Additionally, adherence to local regulations and guidelines for its use and disposal is essential to ensure environmental and personal safety.
Check Digit Verification of cas no
The CAS Registry Mumber 847608-28-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,4,7,6,0 and 8 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 847608-28:
(8*8)+(7*4)+(6*7)+(5*6)+(4*0)+(3*8)+(2*2)+(1*8)=200
200 % 10 = 0
So 847608-28-0 is a valid CAS Registry Number.
847608-28-0Relevant articles and documents
Potent and selective mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors. 1. 4-(4-bromo-2-fluorophenylamino)-1-methylpyridin-2(1h)-ones
Wallace, Eli M.,Lyssikatos, Joseph,Blake, James F.,Seo, Jeongbeob,Yang, Hong Woon,Yeh, Tammie C.,Perrier, Michele,Jarski, Heidi,Marsh, Vivienne,Poch, Gregory,Livingston, Michelle Goyette,Otten, Jennifer,Hingorani, Gary,Woessner, Rich,Lee, Patrice,Winkler, James,Koch, Kevin
, p. 441 - 444 (2007/10/03)
The role of MEK 1,2 in cancer tumorgenesis has been clearly demonstrated preclinically, and two selective inhibitors are currently undergoing clinical evaluation to determine their role in the human disease. We have discovered 4-(4-bromo-2-fluorophenylamino)-1-methylpyridin-2(1H)-ones as a new class of ATP noncompetitive MEK inhibitors. These inhibitors exhibit excellent cellular potency and good pharmacokinetic properties and have demonstrated the ability to inhibit ERK phosphorylation in HT-29 tumors from mouse xenograft studies.